Predictors of 12‐week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study

Kim, Jae Min; Kim, Sung Wan; Stewart, Robert; Kim, Seon‐Young; Yoon, Jin Sang; Jung, Sung Won; Lee, Min-Soo; Yim, Hyeon Woo; Jun, Tae-Won

doi:10.1002/hup.1168

Cited by 39 publications

(31 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Response rates did not significantly differ for treatment with escitalopram, sertraline and venlafaxine-XR. Demographic, social and clinical history factors associated with antidepressant response ratesdsuch as gender (Young, 2009;Thiels et al, 2005), age (Morishita and Kinoshita, 2008), depression subtype (McGrath et al, 2008;Howland et al, 2008;Silverstein and Patel, 2011) and comorbidity (Howland et al, 2009;Kim et al, 2011)d also did not differ for treatments.…”

Section: Discussionmentioning

confidence: 90%

The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment

Saveanu

Etkin

Duchemin

et al. 2015

Journal of Psychiatric Research

131

116

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 90%

The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment

Saveanu

Etkin

Duchemin

et al. 2015

Journal of Psychiatric Research

131

116

View full text Add to dashboard Cite

“…The design and procedure of the study have also been described elsewhere 15. In total, 18 hospitals (16 university and 2 general hospitals) are collaborating in the ongoing CRESCEND study.…”

Section: Methodsmentioning

confidence: 99%

Antidepressant Prescribing Patterns in Korea: Results from the Clinical Research Center for Depression Study

Bae

Kim

et al. 2011

Psychiatry Investig

Self Cite

View full text Add to dashboard Cite

ObjectiveThis study aimed to investigate antidepressant prescribing patterns, including initial choice, switching and combining, and concomitant use of non-antidepressant agents, for depressive disorders in naturalistic clinical care settings in Korea.MethodsPatients with depressive disorder were recruited from both outpatient and inpatient settings in 18 hospitals from all over Korea. Treatment was performed in naturalistic patterns based on each clinician's decision. Data were collected on the prescription of antidepressants and concomitant agents from baseline to 12-week follow-up.ResultsSelective serotonin reuptake inhibitors (SSRIs) were the most commonly prescribed initial antidepressant (48.9%), followed by newer dual-action antidepressants (45.8%). When an SSRI was the initial antidepressant, 46.2% of patients whose medication was changed were moved to newer dual-action antidepressants, and 67.4% of combination cases were combined with newer dual-action ones. When a newer dual-action antidepressant was the initial antidepressant, 70.6% of patients whose medication was changed were moved to SSRIs, and other antidepressants including tricyclic antidepressants were most commonly added for combination treatment (50% of combination cases). During the treatment period, 20.6% of antidepressants prescribed were augmented by non-antidepressant agents, and 75.1% were used concomitantly with anxiolytics or hypnotics. The most commonly used concomitant non-antidepressant agent was quetiapine.ConclusionThe selection of antidepressants and the concomitant use of non-antidepressant agents are becoming increasingly diversified, and the results of this study reflect changes in the prescribing pattern in actual Korean practices.

show abstract

“…One possible reason for the high cost despite the wide range of treatments available is that a high percentage of patients do not reach and sustain remission [3][4][5][6][7] . This hypothesis is supported by a recent study, using the United Kingdom's large General Practice Research Database, of 88,935 individuals who had started an antidepressant 8 .…”

Section: Introductionmentioning

confidence: 99%

Impact of non-remission of depression on costs and resource utilization: from the COmorbidities and symptoms of DEpression (CODE) study

Dennehy

Robinson

Stephenson

et al. 2015

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

Predictors of 12‐week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study

Abstract: Remission associated with unrestricted clinical interventions was comparable to STAR*D estimates for citalopram alone. Comorbid anxiety and previous suicide attempt were markers of worse outcome.

Cited by 39 publications

References 36 publications

The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment

The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment

Antidepressant Prescribing Patterns in Korea: Results from the Clinical Research Center for Depression Study

Impact of non-remission of depression on costs and resource utilization: from the COmorbidities and symptoms of DEpression (CODE) study

Contact Info

Product

Resources

About